ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 42 for:    Microcephaly

Zika Virus Infection's Pregnancy Consequences in French Department of America (ZIKA-DFA-FE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02916732
Recruitment Status : Recruiting
First Posted : September 27, 2016
Last Update Posted : September 27, 2016
Sponsor:
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary:
The Zika (ZIKV) epidemic has spread into the three French Overseas Departments in the Caribbean (DFAs). It is therefore urgent to set up tools to collect clinical and paraclinical data for the evaluation of potential complications due to having ZIKV infection during pregnancy. This study is meant to collect, within usual care practices, clinical and paraclinical information which will allow the precise description of the consequences of ZIKV infection occurring during pregnancy.

Condition or disease
Incidence of ZIKV Infection on Fetus During the Pregnancy

Detailed Description:
This is a prospective observational, non-interventional study that has been integrated into the usual standard of care practices. All information and biological samples collected during the course of this project will be done through the new medical standard of care which has been put in place during the ZIKV epidemic in the DFAs; this new standard of care is a result of existing recommendations from medical professionals and/or public health authorities. Outside of these recommendations, no invasive procedure will be done simply to satisfy an objective of this study.

Study Type : Observational [Patient Registry]
Estimated Enrollment : 26980 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 9 Months
Official Title: Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016
Study Start Date : April 2016
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Zika Virus

Group/Cohort
Module 1
Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
Module 2
Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
Module 3
Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
Module 4
Biological collection of maternal blood and cord blood collected during the delivery
Module 5
Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise



Primary Outcome Measures :
  1. Incidence of ZIKV infection during pregnancy [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Incidence of microcephaly and other fetal abnormalities [ Time Frame: 12 month ]

Other Outcome Measures:
  1. Analysis of risk factor for the occurence of congenital abnormalities [ Time Frame: 12 month ]

Biospecimen Retention:   Samples With DNA
  • bio-bank of serum from all pregnant women.
  • bio-bank of maternal blood and infant cord blood
  • bio-bank of maternal blood and fetal tissues


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The population of this study is women who have been pregnant during the 2016 ZIKV Epidemic in the DFAs. Five study arms (hereafter called 'modules') have been defined with various inclusion criteria for each module.

M1: Pregnant women with clinical signs of acute ZIKV infection

Module 2: Pregnant women for which an abnormality has been detected in the fetus.

Module 3: Bio-bank of serum, collected once per trimester, from all pregnant women.

Module 4: Bio-bank of maternal blood and infant cord blood, taken the day of birth in all mothers and their babies in the 3 DFAs.

Module 5: Bio-bank of maternal blood and fetal tissues from women in whom the pregnancy was terminated due to miscarriage, abortion on medical grounds, or a fetal death in-utero.

Criteria

M1:

Inclusion Criteria:

  • On-going pregnancy regardless the presumed date of birth
  • Clinical signs suggestive of ZIKV infection
  • Whatever the RT-PCR analysis

Exclusion Criteria:

  • Minor
  • No consent

M2:

Inclusion Criteria:

  • Head circumference < 5th percentile
  • Other brain morphological abnormality
  • Hydramnios
  • Intrauterine growth restriction (IUGR)

Exclusion Criteria:

  • Minor
  • No consent

M3:

Inclusion Criteria:

  • Pregnant woman during epidemic period of ZIKV

Exclusion Criteria:

  • Minor
  • Opposition

M4:

Inclusion Criteria:

  • Delivery during epidemic period of ZIKV

Exclusion Criteria:

  • Minor
  • No consent

M5:

Inclusion Criteria:

  • Spontaneous abortion or fetal death in utero during epidemic period of ZIKV

Exclusion Criteria:

  • Minor
  • No consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02916732


Contacts
Contact: Bruno Hoen bruno.hoen@chu-guadeloupe.fr

Locations
France
CH Andrée Rosemon (CHAR) Recruiting
Cayenne Cedex, France, 97306
CHU de Martinique Recruiting
Fort de France Cedex, France, 97261
CHU de Pointe à Pitre/Les Abymes Recruiting
Pointe A Pitre, France, 97139
CH de l'Ouest Guyanais Franck Joly (CHOG) Recruiting
Saint-laurent-du-maroni, France, 97320
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier: NCT02916732     History of Changes
Other Study ID Numbers: C16-08
2016-A00399-42 ( Other Identifier: France ANSM )
First Posted: September 27, 2016    Key Record Dates
Last Update Posted: September 27, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
asymptomatics
microcephaly
abnormalities

Additional relevant MeSH terms:
Infection
Zika Virus Infection
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections